Press Release: Pulmonx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx" or the "Company"), a glob
Pulmonx Corporation's Financial Outlook: Single-Product Reliance and Market Penetration Hurdles Threaten Profitability
Pulmonx Corporation (NASDAQ:LUNG) Q1 2024 Earnings Call Transcript
Pulmonx Is Maintained at Buy by Canaccord Genuity
Pulmonx Is Maintained at Buy by Canaccord Genuity
Canadian Investment Banking Group: Maintaining the Pulmonx (LUNG.US) rating, adjusted from a buy rating to a buy rating, and the target price was adjusted from $16.00 to $15.00.
Canadian Investment Banking Group: Maintaining the Pulmonx (LUNG.US) rating, adjusted from a buy rating to a buy rating, and the target price was adjusted from $16.00 to $15.00.
Canaccord Genuity Maintains Buy on Pulmonx, Lowers Price Target to $15
Canaccord Genuity analyst Jon Young maintains Pulmonx (NASDAQ:LUNG) with a Buy and lowers the price target from $16 to $15.
Pulmonx Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 51.67% Canaccord Genuity $16 → $15 Maintains Buy 04/03/2024 71.89% Piper Sandler $17 → $17 Reit
C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Dow Jones index gaining over 50 points on Thursday.Shares of C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) rose sharply during Thursday's session after the company repo
Pulmonx Surge After Strong 1Q Performance
By Dean Seal Shares of Pulmonx soared after the company logged a narrower first-quarter loss than analysts had been expecting. The stock was up 25% at $9.63 after the opening bell. Shares are still
Market-Moving News May 2nd
ALLR: 151% | Allarity Therapeutics shares are trading higher after the company announced that Stenoparib shows a clear clinical benefit, leading to early conclusion of the Phase 2 trial in advanced ov
Q1 2024 Pulmonx Corp Earnings Call
Earnings Call: Pulmonx Sees 30% Sales Boost in Q1, Eyes $84M Annual Target
Earnings Call Summary | Pulmonx(LUNG.US) Q1 2024 Earnings Conference
The following is a summary of the Pulmonx Corporation (LUNG) Q1 2024 Earnings Call Transcript:Financial Performance:Pulmonx reported Q1 2024 sales of $18.9 million, a 30% increase from the same period
Pulmonx Corp (LUNG) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Improved ...
Pulmonx Corporation (LUNG) Q1 2024 Earnings Call Transcript
Pulmonx Corporation (LUNG) Q1 2024 Earnings Call Transcript
Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates
Pulmonx Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
Pulmonx Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
Pulmonx Sees FY24 Revenue $81M-$84M Vs $82.189M Est.
Pulmonx Sees FY24 Revenue $81M-$84M Vs $82.189M Est.
Pulmonx Q1 2024 GAAP EPS $(0.36) Beats $(0.46) Estimate, Sales $18.854M Beat $17.893M Estimate
Pulmonx (NASDAQ:LUNG) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.46) by 21.74 percent. This is a 14.29 percent increase over losses of $(0.42) per
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersPulmonx (NASDAQ:LUNG) shares rose 29.5% to $10.0 during Wednesday's after-market session. The market value of their outstanding shares is at $388.1 million. The company's, Q1 earnings came out
No Data